New York, NY (Press Release) – Starton Thera­peutics Inc. (“Starton” or the “Com­pany”), a bio­technol­ogy com­pany focused on trans­forming standard of care thera­peutics, to­day an­nounced that it has filed PCT (“Patent Cooperation Treaty”) and US Non-Provisional pat­ent appli­ca­tions entitled “Continuous Delivery of Lena­lido­mide and Other Immuno­modu­la­tory Agents” on April 21, 2020 (PCT Appli­ca­tion No. PCT/US20/29159 and U.S. Appli­ca­tion No. 16/854,810).

The PCT appli­ca­tion, filed with the PCT re­ceiv­ing office at the U.S. Patent & Trademark Office, allows Starton to file pat­ent appli­ca­tions to seek pro­tec­tion for the methods disclosed therein in most major …

New York, NY (Press Release) – Starton Thera­peutics Inc. (“Starton” or the “Company”), a bio­technol­ogy com­pany focused on trans­forming standard of care thera­peutics, to­day an­nounced the com­ple­tion of a proof of concept study of multiple myeloma with lena­lido­mide using a model which emulates trans­dermal de­livery. The results of the study dem­onstrate that a con­tin­uous sub­cu­tane­ous (SC) de­livery of lena­lido­mide is superior in terms of efficacy and equivalent in tolerability when com­pared to a standard once daily pulsatile dosing of Revlimid® (Celgene Corpo­ra­tion) in mice. The pos­i­tive out­come provides a clear path for de­vel­op­ment …

New York, NY (Press Release) – ChemioCare USA Inc. (“ChemioCare” or the “Company”), a plat­form com­pany focused on pro­pri­e­tary trans­dermal delivery, announced today the Company is initiating devel­op­ment of a trans­dermal for­mu­la­tion of lena­lido­mide, which is cur­rently marketed in an oral form. ChemioCare believes that by applying its permeation en­hanced trans­dermal tech­nology (PETT), it can poten­tially target and deliver the optimal con­tin­uous lena­lido­mide AUC (drug level area under the curve) that may lead to reduced drug toxicity and im­prove­ment in the over­all safety profile of the drug. These im­prove­ments can be ex­pec­ted to …